NHS Approves First Daily Pill for Endometriosis Treatment in England and Wales
The first-ever daily pill for treating endometriosis symptoms has been approved for use on the NHS in England and Wales, but only for patients who have exhausted all other treatment options.
Endometriosis affects 1.5 million women in the UK, causing severe pain, fatigue, and fertility issues due to tissue similar to the womb lining growing outside the uterus.
New Endometriosis Pill: Relugolix Combination Therapy
The newly approved relugolix combination therapy offers an alternative to current injectable treatments, allowing patients to take the medication at home. Approved by the National Institute for Health and Care Excellence (NICE), the pill blocks specific hormones responsible for endometriosis while also providing essential hormone replacements.
Key Benefits of the Endometriosis Pill
Who Can Get the New Endometriosis Pill on the NHS?
NICE has approved the medication only for women who have tried all other medical and surgical options without success. This includes hormonal contraceptives, intrauterine devices (IUDs), and hormone injections.
- Convenient Home Treatment – No hospital visits for injections.
- Easier to Start and Stop – Helpful for women planning pregnancy.
- Costs £72 for a 28-Day Supply – Funded by the NHS for eligible patients.
- Reduces Pressure on NHS Services – Minimizes hospital visits.
Symptoms of Endometriosis
- Severe period pain that disrupts daily life
- Heavy menstrual bleeding
- Painful urination or bowel movements
- Lower abdominal pain and pain after intercourse
- Extreme fatigue, anxiety, and low mood
- Difficulty getting pregnant
Endometriosis Patients Share Their Struggles
Ami Clarke, 27, from St Albans, suffered from excruciating pain since her first period at age 13. Misdiagnosed for 10 years, she tried six different contraceptive pills, underwent two surgeries, and still faces unbearable pain.
I wasn’t going to university, I wasn’t going to work. If I was going, I was collapsing in pain every month, she told the BBC.
Ami believes the new treatment offers hope but insists more investment in endometriosis research is needed.
Why Was the Pill Initially Rejected?
NICE first rejected the drug, but new evidence from the manufacturer demonstrated its effectiveness and cost-efficiency.
Looking Ahead: More Research Needed
While this daily pill is a breakthrough, experts emphasize the need for further research into better treatments for endometriosis.
